News

GlaxoSmithKline (GSK) and Theravance, Inc. recently announced in a press release their plans to file for a joint-supplemental Japanese New Drug Application (sJNDA) for their collaboratively developed chronic obstructive pulmonary disease (COPD) treatment, Relvar® Ellipta® (fluticasone furoate “FF”/vilanterol “VI” or “FF/VI” or Breo Ellipta). The partners aim to submit the application…

Recent data obtained from a study published in the International Journal of Chronic Obstructive Pulmonary Disease entitled “Benzodiazepine use in COPD: empirical evidence from Norway“ highlighted the misuse of benzodiazepine sedatives among COPD patients. The data, which was taken from the Norwegian Patient Register…

Bracket, an electronic Clinical Outcomes Assessments (eCOA) provider, recently announced that the company has completed a key certification along with partner Evidera™ for the EXACT patient daily e-Diary to be used on the Android mobile platform. By reaching this certification milestone, the Bracket eCOA solution is now the only certified provider of this technology for use on…

Theravance Biopharma, Inc. and Mylan MYL recently announced the commencement of a new phase III clinical program to evaluate revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) being developed to treat chronic obstructive pulmonary disease (COPD). The Phase III clinical program involves two replicate, randomized, placebo-controlled, double-blind, parallel-group,…

Minnesota Health Solutions Corporation (MHS) recently announced a partnership with Novu, an SaaS-based consumer engagement platform designed to align consumers and the health care ecosystem. The partnership will provide a digitally-delivered program to motivate and monitor patients with Chronic Obstructive Pulmonary Disorder (COPD), a condition which, along with all chronic lower respiratory…

Prescribing bronchodilators for patients with chronic obstructive pulmonary disease (COPD) with varying levels of disease severity can be a difficult task for clinicians and healthcare professionals. Of late, several combinations of bronchodilators were approved for patient use in COPD and other respiratory diseases. In a recent article entitled “Comparative efficacy of…

The use of short-acting-beta-2-agonists (SABA) has been associated with prediction of increased risks of chronic obstructive pulmonary disease (COPD) exacerbations in patients, according to a recent study entitled “Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease” published in…

ieCrowd™ recently announced the achievement of a crucial milestone in the commercial advancement of Smart Oxygen, the firm’s supplemental oxygen delivery device. The Smart Oxygen device is being advanced by ieCrowd’s subsidiary Smart Oxygen Solutions and has the ability to automatically adjust to the patient’s need for oxygen, even if those demands are constantly changing, through analyzing the level of…

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by progressive breathlessness, acute exacerbations, increased coughing, mucus, and a feeling of tightness in patients’ chest. Usually if the exacerbation symptoms are not detected and treated on time, they can escalate, leading to a more acute scenario, which can diminish…

In a recent article published in the Polish Archives of Internal Medicine, Richard ZuWallack from the Department of Pulmonary and Critical Care, St. Francis Hospital and Medical Center in Hartford, Connecticut conducted a review exploring the concept of physical activity in patients with Chronic Obstructive Pulmonary Disease.